Stockscreener 앱 받기
17.63
0.63%
0.11
시간 외 거래:
17.74
0.11
+0.62%
Beam Therapeutics Inc 주식(BEAM)의 최신 뉴스
BEAM-101 Receives RMAT for the Treatment of Sickle Cell Disease - Pharmacy Times
Beam Therapeutics Stock Surges After FDA Grants RMAT Designation - MSN
Beam Therapeutics stock surges after FDA grants RMAT designation By Investing.com - Investing.com Canada
Beam Therapeutics stock surges after FDA grants RMAT designation - Investing.com
Beam Therapeutics Gets FDA Regenerative Medicine Status for BEAM-101 to Treat Sickle Cell Disease - MarketScreener
Beam gains FDA Regenerative Medicine Advanced Therapy status for sickle cell treatment - Seeking Alpha
Beam Therapeutics' Sickle Cell Treatment Gets FDA's Generative Medicine Advanced Therapy Designation - MarketWatch
Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | BEAM Stock News - GuruFocus
FDA grants RMAT designation to Beam Therapeutics’ sickle cell therapy By Investing.com - Investing.com Australia
FDA grants RMAT designation to Beam Therapeutics’ sickle cell therapy - Investing.com
Beam Therapeutics Announces U.S. FDA Regenerative Medicine - GlobeNewswire
Beam's Sickle Cell Gene Therapy Gets FDA Speed Boost After Strong Trial Data in 30 Patients - Stock Titan
Can Rising Casgevy Sales Aid CRISPR Therapeutics Post Q2 Earnings? - Yahoo Finance
Will Beam Therapeutics Inc. benefit from government policyROI-Driven Capital Plans - thegnnews.com
Beam Therapeutics (NASDAQ:BEAM) Price Target Cut to $21.00 by Analysts at Barclays - MarketBeat
Beam Therapeutics Inc. Recovery Gathers Momentum on Chart SignalsFree Access to Community - beatles.ru
BEAM's Q2 Loss Narrower Than Expected, Revenues Miss Mark - MSN
Beam Therapeutics: Analyst Maintains Buy Rating Amid Promising Trials and Solid Financials - AInvest
Beam Therapeutics: A Promising Genetic Medicine Player with Multiple Upcoming Catalysts - AInvest
H.C. Wainwright Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $80 - 富途牛牛
Leerink Partners Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Announces Target Price $42 - 富途牛牛
Beam Therapeutics Receives Buy Rating from Leerink Partners with $42 Price Target - AInvest
Beam Therapeutics Reports Q2 2025 Financials, Promising BEAM-302 Results in AATD Trial and Completion of BEACON Trial for Sickle Cell Disease. - AInvest
Beam Therapeutics Reports Q2 Revenue Below Consensus, Highlights Clinical Progress in Priority Programs - AInvest
Beam Therapeutics: A Narrower Loss in Q2 2025—Sign of a Sustainable Turnaround or a Temporary Bounce? - AInvest
Beam Therapeutics 2025 Q2 Earnings Net Loss Widen Despite EPS Improvement - AInvest
BEAM: Barclays Lowers Price Target with Equal-Weight Rating | BE - GuruFocus
Positive Developments and Financial Strength Bolster Beam Therapeutics’ Buy Rating - TipRanks
Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates - MSN
Beam Therapeutics Reports Q2 2025 Financial Results - TipRanks
Decoding Beam Therapeutics Inc (BEAM): A Strategic SWOT Insight - GuruFocus
Evaluating the High-Growth Potential of Biopharma Innovators in 2025: A Deep Dive into Day One, Beam Therapeutics, and Syndax Pharmaceuticals - AInvest
Beam Therapeutics shares fall 1.59% intraday after Q2 net loss widens more than expected. - AInvest
Clear Street reiterates Buy rating on Beam Therapeutics stock at $34 - Investing.com
Beam Therapeutics Q2 Net Loss Narrows, Revenue Falls - MarketScreener
Beam Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Beam Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Beam (BEAM) Advances in AATD Treatment with Promising BEAM-302 T - GuruFocus
BEAM Reports Q2 Revenue Below Consensus and Highlights Significa - GuruFocus
Beam Therapeutics Inc Reports Q2 2025 EPS of -$1.00, Beating Est - GuruFocus
Beam Therapeutics Q2 net loss widens more than expected - MarketScreener
Beam Therapeutics Inc. SEC 10-Q Report - TradingView
Earnings Flash (BEAM) Beam Therapeutics Posts Q2 $1 Loss, vs. FactSet Est of $1.11 Loss - MarketScreener
Beam Therapeutics Reports Positive Clinical Updates for BEAM-302 and BEAM-101, Financial Results for Q2 2025 - Quiver Quantitative
Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD) - The Manila Times
Beam Therapeutics Reports Second Quarter 2025 Financial - GlobeNewswire
Beam Therapeutics' AATD Treatment Achieves Major Clinical Milestone: 17 Patients Show Durable Disease Correction - Stock Titan
Beam Therapeutics Reports Second Quarter 2025 Financial Results - GuruFocus
When is Beam Therapeutics Inc. stock expected to show significant growthBuild a diversified portfolio for steady growth - Jammu Links News
What makes Beam Therapeutics Inc. stock price move sharplyCapitalize on momentum-driven stocks - Jammu Links News
How many analysts rate Beam Therapeutics Inc. as a “Buy”Unlock real-time stock alerts for quick profits - Jammu Links News
Is it the right time to buy Beam Therapeutics Inc. stockAchieve rapid portfolio growth with expert help - Jammu Links News
Why is Beam Therapeutics Inc. stock attracting strong analyst attentionGrow your wealth with proven stock picks - Jammu Links News
How volatile is Beam Therapeutics Inc. stock compared to the marketMaximize your portfolio’s growth potential - Jammu Links News
What is the risk reward ratio of investing in Beam Therapeutics Inc. stock - Jammu Links News
What are Beam Therapeutics Inc. company’s key revenue driversBoost your returns with professional guidance - Jammu Links News
Is Beam Therapeutics Inc. stock overvalued or undervaluedFree Predictions - Jammu Links News
0.11%
1.56%
자본화:
|
볼륨(24시간):